文献速递临床试验与 GCP

奥美沙坦/氨氯地平晨服或夜服对中国轻度至中度原发性高血压患者夜间降压效果的影响(OMAN试验):一项前瞻性、多中心、随机、开放标签临床试验的研究方案

The effects of Olmesartan/amlodipine administered in the Morning or At Night on nocturnal blood pressure reduction in Chinese patients with mild-moderate essential hypertension (OMAN Trial): study protocol for a prospective, multicenter, randomized, open-label clinical trial {1}.
PubMed 文献 · Trials · 2023-11-28

本研究为前瞻性、多中心、随机、开放标签平行组临床试验,计划纳入720例中国轻度至中度原发性高血压患者,基线行24小时动态血压监测和诊室血压测量后随机分为晨服组(6-10点)或睡前服组(6-10点),每日服用奥美沙坦/氨氯地平20/5 mg片剂1片,随访12周,主要终点为基线至第12周夜间平均收缩压降幅。

要点

  • 未控制夜间血压在服用降压药患者中发生率为30-60%。
  • 研究比较晨服与睡前服奥美沙坦/氨氯地平对夜间血压及昼夜节律的影响。
  • 主要终点为基线至第12周夜间平均收缩压降幅。

核心结论

  • 研究旨在确定中国原发性高血压患者夜间血压控制是否因晨服或睡前服降压药而异。
  • 本研究或为时间治疗学在临床实践中的应用提供科学证据。

研究设计与样本

  • 前瞻性、多中心、随机、开放标签、平行组临床试验。
  • 计划纳入720例参与者,基线行24小时动态血压监测和诊室血压测量后随机分入晨服组(6-10点)或睡前服组(6-10点)。
  • 每人每日服用奥美沙坦/氨氯地平20/5 mg片剂1片,共4周,此后每4周随访一次,共12周。
  • 随访期间根据动态血压和诊室血压结果调整奥美沙坦/氨氯地平剂量;首次随访血压未控制者增至1.5片/日;再4周后仍未控制者可增至2片/日。

关键数值与推荐

  • 主要目标为基线至第12周夜间平均收缩压降幅。
  • 次要目标为第4周和第12周动态血压降幅及第4、8、12周血压控制率。
  • 采用优效性检验假设设计,所有参与者服用同一降压药物。

局限性

  • 降压时间治疗学仍存在争议,临床证据基础仍有争议。
  • 本研究仍在进行中,尚未报告结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hypertension increases the risk of cardiovascular disease. Uncontrolled nocturnal blood pressure is prevalent in patients taking antihypertensive medication, with an incidence rate of 30-60%. Although chronotherapy with antihypertensive agents may provide a new direction for effective control of nocturnal blood pressure, the clinical evidence base remains controversial. This research is presently underway to compare the effects of morning and bedtime administration of antihypertensive medication on nocturnal reduction and circadian rhythm of blood pressure in patients with hypertension. METHODS AND ANALYSIS: This study is being performed as a randomized, multicenter, open-label, parallel-group, clinical trial in which 720 participants are to undergo 24-h ambulatory blood pressure measurement (ABPM) and office blood pressure measurement (OBPM) at baseline before being randomly assigned to a morning (6-10 am) or a bedtime (6-10 pm) administration group. Each participant receives one 20/5-mg tablet of olmesartan/amlodipine (OA) daily for 4 weeks and is then followed up at 4-week intervals for a total of 12 weeks. During follow-up, the OA dosage is adjusted according to the ABPM and OBPM results. Patients with uncontrolled hypertension at the first follow-up visit will receive an increase in OA dosage to 1.5 tablets/day. For patients with blood pressure that is still uncontrolled after a further 4 weeks, the dosage of OA can be increased to 2 tablets/day. The primary objective is the reduction in mean nocturnal systolic blood pressure between baseline and week 12. The secondary objectives are the reduction in ambulatory blood pressure at weeks 4 and 12 and the blood pressure control rate at weeks 4, 8, and 12. DISCUSSION: Antihypertensive chronotherapy remains controversial. A superiority test hypothesis design has been adopted for this trial, in which all participants will be taking the same antihypertensive medication. We anticipate that our findings will determine if nocturnal blood pressure control in Chinese patients with essential hypertension varies according to whether antihypertensive medication is taken in the morning or at bedtime. This study may provide scientific evidence for the application of chronotherapy in clinical practice. TRIAL REGISTRATION: ChiCTR2200059719. Registered on 10 May 2022 ( http://www.chictr.org.cn/edit.aspx?pid=169782&htm=4 ) {2a,2b}.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Xu M, Zhang X, Ye R, et al. The effects of Olmesartan/amlodipine administered in the Morning or At Night on nocturnal blood pressure reduction in Chinese patients with mild-moderate essential hypertension (OMAN Trial): study protocol for a prospective, multicenter, randomized, open-label clinical trial {1}. Trials. 2023. PMID: 38017457. doi:10.1186/s13063-023-07726-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。